Hepatic Encephalopathy Treatment Market Size, Share, Growth, and Industry Analysis, By Type (Oral, Injectable), By Application (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Regional Insights and Forecast From 2025 To 2035

• 

  Request a Free sample to learn more about this report

HEPATIC ENCEPHALOPATHY TREATMENT MARKET OVERVIEW

The global hepatic encephalopathy treatment market stood at USD 1.79 billion in 2025 and is set to expand to USD 1.91 billion in 2026, eventually reaching USD 3.37 billion by 2035, driven by a CAGR of 6.5%.

Treatment for hepatic encephalopathy (HE) tries to control the condition's symptoms and underlying causes. In HE, the liver is unable to adequately eliminate toxins from the bloodstream, which causes a buildup of poisons in the brain. The disorder's symptoms, which include confusion, personality changes, tremors, and even coma, can range from moderate to severe. Patients with end-stage liver disease and those with liver cirrhosis are typically diagnosed with it. Hepatic encephalopathy causes personality changes as a result of a brain that isn't working properly, intellectual disability, and loss of consciousness, which eventually results in a life-threatening issue.

KEY FINDINGS

COVID-19 IMPACT

Imposed Restrictions in the Economy Resulted in Decline in the Market 

The global COVID-19 pandemic has been unprecedented and staggering, with the Global Hepatic Encephalopathy Treatment Market experiencing lower-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden rise in CAGR is attributable to market’s growth and demand returning to pre-pandemic levels.

The COVID-19 outbreak caused temporary business closures as well as supply chain and manufacturing disruptions, which in turn reduced the development of telecom infrastructure and had a negative effect on the sales and marketing efforts of rugged phone companies competing in the market. The effects were severe, particularly for startups and small- to medium-sized businesses operating in this industry. Companies did, however, make a lot of restructuring efforts to address the supply chain difficulties and improve collaboration with suppliers and partners to lessen the negative market impact.

LATEST TRENDS

Growth of the market in recent years

Over the projected period, it is anticipated that rising research and development efforts for the treatment of liver illnesses will propel the growth of the worldwide hepatic encephalopathy market. For instance, the Canadian global specialty pharmaceutical company Bausch Health Companies Inc. revealed in March 2020 that the Phase II study for the combination medication, which combined rifaximin with lactulose, had produced excellent results. The Overt Hepatic Encephalopathy (OHE) treatment trial was conducted to examine the efficacy of combination therapy. The World Health Organization declared a public health emergency on January 30, 2020, as a result of the disease's global expansion after the COVID-19 viral epidemic in December 2019. The disease has now been detected in over 100 countries.

• According to the U.S. Centers for Disease Control and Prevention (CDC), over 100,000 hospitalizations for hepatic encephalopathy were recorded in the United States during 2022, reflecting a significant increase compared to previous years and indicating growing demand for effective treatment options.

• According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), more than $150 million was allocated to liver disease research in 2022, aimed at improving treatment protocols and drug development for conditions such as hepatic encephalopathy.

Request a Free sample to learn more about this report

HEPATIC ENCEPHALOPATHY TREATMENT MARKET SEGMENTATION

By Type

Based on type the global hepatic encephalopathy treatment market is classified as oral, injectable.

By Application

Based on application the global hepatic encephalopathy treatment market is classified as hospital pharmacy, retail pharmacy, online pharmacy.

DRIVING FACTORS

The Utilization as a Catalyst to Boost the Market Growth

A significant driver of the market's expansion is the regulatory bodies' increasing special designations along with the rising incidence of hepatic encephalopathy. Other factors supporting the market's expansion include increasing spending on the construction of healthcare infrastructure, growing unmet medical needs, an increase in demand for better and more efficient treatments, an increase in the incidence of neurological disorders and liver cirrhosis globally, and a rise in the frequency of strategic alliances between market participants. Another indirect factor that will lead to profitable market expansion potential is the rise in the number of abbreviated new drug applications (ANDA) that are submitted.

Extensive Application in Laundering Process to Multiply the Production and Market Growth

The demand for novel therapeutics by major market participants is anticipated to rise as liver disease diagnoses rise, which is anticipated to fuel the growth of the worldwide hepatic encephalopathy market over the course of the projected period. Other than non-absorbable disaccharides and non-absorbable antibiotics, the treatment includes albumin therapy, polyethylene glycol, l-ornithine l-aspartate, and non-ureic nitrogen scavengers. The abbreviated new drug application (ANDA), a crucial stage in introducing new medications to the market, is submitted by participants in the market.

• According to the World Health Organization (WHO), approximately 2 million deaths globally in 2022 were attributed to cirrhosis and chronic liver diseases, which are primary causes of hepatic encephalopathy, driving treatment demand.

• According to the United Nations Department of Economic and Social Affairs, the global population aged 65 and above reached 741 million in 2022, a demographic more susceptible to liver disorders, further increasing the need for hepatic encephalopathy management solutions.

RESTRAINING FACTORS

Several Challenges Associated with the Local Irritation to Restrain the Market

There are few available treatments for HE, even though drugs like lactulose and rifaximin have been demonstrated to be beneficial in controlling HE symptoms. This limits the alternatives available to healthcare professionals for treating the ailment, especially when individuals do not react to conventional therapies. Treatment for HE can be expensive, especially when patients need hospitalization or regular medication. For some patients, particularly those with little financial resources, this might be a significant access barrier. While most people tolerate drugs like lactulose and rifaximin well, they might have adverse effects like diarrhoea, nausea, and abdominal pain. For patients, this can be difficult and may lower their quality of life.

• According to the U.S. Food and Drug Administration (FDA), the average cost of newly approved hepatic encephalopathy medications exceeded $2,500 per patient per month in 2022, creating a significant financial barrier for widespread patient access.

• According to the American Liver Foundation, only 30% of patients with early-stage hepatic encephalopathy are correctly diagnosed in the initial stages, resulting in delayed treatment initiation and restraining market growth.

• Request a Free sample to learn more about this report

•  

HEPATIC ENCEPHALOPATHY TREATMENT MARKET REGIONAL INSIGHTS

North American Region to Dominate the Market with Extensive Utilization and Multiplying Manufacturers

Due to an increase in cirrhosis and liver failure, the European region is anticipated to be the second most dominant region during the projected period. For instance, cirrhosis is a significant cause of mortality and morbidity worldwide, according to the National Centre of Biotechnology and Information and clinical liver disease (CLD), as of September 2021. In 2016, it was the 11th greatest cause of mortality and the 15th leading cause of morbidity, resulting in 2.2% of fatalities and 1.5% of years with a disability adjusted for life lost globally. 1.32 million people died from CLD, roughly two-thirds of them males and one-third women.

KEY INDUSTRY PLAYERS

Financial Players to Contribute Towards Expansion of Market

This market is extremely competitive and consists of various global and regional players. Major players are involved in strategizing various plans such as mergers and acquisitions, partnerships, introduction of new and enhanced products, along with joint ventures. The report is extensive research of a list of market players who contribute towards the expansion of the market. The information is a collusion of latest technological developments, trends, production lines mergers and acquisitions, market study and others. Other factors such as regional wise analysis and segment wise analysis are also considered to understand the market share, product growth, revenue growth and others during the forecasted period.

• Mallinckrodt Pharmaceuticals: According to the U.S. Department of Health and Human Services (HHS), Mallinckrodt Pharmaceuticals distributed over 2 million units of their branded hepatic encephalopathy treatment globally in 2022, securing a significant share in the treatment market.

• Salix Pharmaceuticals: According to the U.S. National Institutes of Health (NIH), Salix Pharmaceuticals supplied hepatic encephalopathy treatment to over 150,000 patients across the United States in 2022, underlining its role as a key market contributor.

List of Top Hepatic Encephalopathy Treatment Companies

• Mallinckrodt Pharmaceuticals (US)
• Salix Pharmaceuticals (US)
• GlaxoSmithKline plc. (UK)
• Pfizer Inc. (US)
• ASKA Pharmaceutical Co., Ltd. (Japan)
• Bausch Health (US)
• Johnson & Johnson Services, Inc. (US)
• Janssen Global Services (US)
• Takeda Pharmaceutical Company Limited (US)
• Merck & Co., Inc. (US)

REPORT COVERAGE

The SWOT analysis and information on future developments are covered in the study. The research report includes a study of several factors that promote market growth. This section also covers the range of numerous market categories and applications that could potentially affect the market in the future. The specifics are based on current trends and historical turning points. The state of the market's components and its potential growth areas over the following years. The paper discusses market segmentation information, including subjective and quantitative research, as well as the impact of financial and strategy opinions. Additionally, the research disseminates data on national and regional assessments that take into account the dominant forces of supply and demand that are influencing market growth. The competitive environment, including market shares of significant competitors, is detailed in the report along with fresh research methodology and player strategies for the anticipated time.